Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

<p>Abstract</p> <p>Background</p> <p>This study investigated the cardiovascular (CV) safety profile of the dipeptidyl peptidase (DPP)-4 inhibitor linagliptin versus comparator treatments.</p> <p>Methods</p> <p>This was a pre-specified meta-analys...

Full description

Bibliographic Details
Main Authors: Johansen Odd, Neubacher Dietmar, von Eynatten Maximilian, Patel Sanjay, Woerle Hans-Juergen
Format: Article
Language:English
Published: BMC 2012-01-01
Series:Cardiovascular Diabetology
Subjects:
Cardiovascular risk
DPP-4 inhibitor
linagliptin
meta-analysis
type 2 diabetes mellitus
Online Access:http://www.cardiab.com/content/11/1/3

Internet

http://www.cardiab.com/content/11/1/3

Similar Items